NCT04499950 2025-03-06
A-NEW
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
6 trialsNCT01650350 2022-03-04
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
Brown University
Phase 2 Terminated
NCT02137252 2021-11-16
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00379197 2017-12-28
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01303835 2015-07-17
Low Dose Naltrexone for Glioma Patients
Duke University
Phase 2 Completed
NCT01100437 2012-07-13
Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients
Pfizer
Phase 4 Terminated